Realize The Full Potential Of Your RNA Therapeutics: Aldevron's Optimized 5' UTR Backbones

High‑quality mRNA production depends on controlling immunogenic byproducts while maintaining yield, integrity, and cost efficiency. Engineered RNA polymerases designed for co‑transcriptional capping address a key bottleneck in in vitro transcription by reducing double‑stranded RNA formation at the source, simplifying downstream purification and improving final product quality. Higher affinity for commonly used cap analogs enables consistently high capping efficiency without depleting critical nucleotides or increasing reagent consumption.

These performance gains translate into practical advantages for mRNA therapeutic workflows, including improved safety profiles, lower processing complexity, and greater flexibility with modified nucleotides such as pseudouridine. Robust performance across a range of transcript lengths further supports scalable manufacturing as programs advance from research to clinical and commercial production.

Explore this brochure to see how optimized transcription chemistry can streamline mRNA manufacturing while supporting regulatory‑ready quality and consistency.